Remedy Meds Review 2026: Pricing, FDA Warning Letter & Alternatives
Remedy Meds is a month-to-month GLP-1 telehealth platform charging $299/month for compounded semaglutide and $399/month for compounded tirzepatide — the highest compounded prices among major platforms, offset by unlimited clinician messaging and video calls. It also carries a September 2025 FDA warning letter for misbranded marketing. This review covers what the premium buys, what the warning letter means, and who should look elsewhere.
What Is Remedy Meds & How Does It Operate?
Remedy Meds is a telehealth weight loss platform built around simplicity: one monthly price per medication, no prepay tiers, no membership fees, cancel anytime. The intake-review-ship process is standard for the category — online health questionnaire, licensed clinician review, pharmacy fulfillment if prescribed. What is not standard is the access model: unlimited video calls and messaging with the care team between monthly check-ins.
Brand-name options exist ($1,299 Ozempic, $1,399 Zepbound) but the platform is clearly compounded-first. For how compounded GLP-1s differ from brand-name, see our compounded semaglutide guide.
The September 2025 FDA Warning Letter, Explained
The FDA cited Remedy Meds for misbranding: marketing that said its compounded tirzepatide and semaglutide contain the same active ingredients as brand-name drugs in a way that implied the products were FDA-approved. Compounded medications are not FDA-approved, and the agency sent warning letters to more than 50 GLP-1 compounders and telehealth marketers in September 2025 over similar equivalency claims.
Practical read: the letter concerned advertising, not a finding that the medication itself was unsafe. But how a platform talks about risk is a reasonable proxy for how it handles everything else patients cannot see. For the broader regulatory picture, see the FDA's GLP-1 compounding crackdown.
Remedy Meds Pricing vs the Market
At $299/month for semaglutide and $399/month for tirzepatide, Remedy Meds sits at the top of the market as of July 2026 — from $2/month above Henry Meds to $165/month above SurpassMD on rolling rates. Over a 12-month course, choosing Remedy Meds over the cheapest tracked alternative costs roughly $1,980 more for semaglutide. The unlimited-access model has real value for patients managing side effects or titrating carefully, but that is the price of it.
Full pricing landscape: GLP-1 telehealth price comparison.
Pros & Cons of Remedy Meds
Pros
- Unlimited video calls and messaging between check-ins
- True month-to-month billing, no prepay pressure
- All-inclusive fee: medication, check-ins, shipping
- Brand-name Ozempic and Zepbound available
Cons
- Highest compounded prices among major platforms ($299/$399)
- September 2025 FDA warning letter for misbranded marketing
- No discount path for long-term users
- No oral medication options
- Compounded medications are not FDA-approved
Remedy Meds Alternatives
Price-first patients should compare SurpassMD vs Remedy Meds (semaglutide $134 vs $299) and TrimRx. Coaching-first patients should look at Fridays. Patients who want oral tirzepatide should see Henry Meds. The full field is ranked in our best GLP-1 telehealth providers guide.
Best for: patients who expect to need frequent provider contact and will actually use unlimited access. Skip if: you are price-sensitive or want prepay discounts for a medication you already tolerate.
Frequently Asked Questions
As of July 2026, Remedy Meds charges $299/month for compounded semaglutide and $399/month for compounded tirzepatide, billed month-to-month. The fee includes medication, monthly clinician check-ins, and unlimited video calls and messaging between check-ins. Brand-name Ozempic ($1,299) and Zepbound ($1,399) are available at additional cost, though availability may be limited.
In September 2025, the FDA issued Remedy Meds a warning letter citing misbranding of its compounded semaglutide and tirzepatide. The agency found the company’s marketing stated its compounded medications contain the same active ingredients as brand-name GLP-1s in a way that implied FDA approval, which compounded drugs do not have. The company continues to operate; the letter concerned advertising claims rather than product safety findings, but it is a relevant data point when evaluating how a platform communicates risk.
No, and this is its main structural advantage. Remedy Meds bills month-to-month with no prepaid tiers, so you are never locked into a 6- or 12-month commitment. The trade-off is price: its $299/$399 rates are the highest compounded GLP-1 prices among major platforms, and there is no discount path for committed users the way Fridays or TrimRx offer.
Yes, at every comparison point as of July 2026. Its $299/month semaglutide compares to $134 at SurpassMD, $179 (first month) at TrimRx, $249 at Fridays, and $297 at Henry Meds. Its $399/month tirzepatide compares to $199 at SurpassMD and $349 at TrimRx. What you get for the premium is unlimited provider messaging and video calls, which most cheaper platforms cap or omit.
Medication, monthly clinician check-ins, and unlimited video calls and messaging between check-ins. There is no separate membership fee, consultation fee, or shipping charge. The unlimited-access model is genuinely unusual — most GLP-1 platforms limit provider contact to scheduled check-ins or async messaging with response-time windows.
For lower cost: SurpassMD (semaglutide from $134/month, tirzepatide from $199/month) or TrimRx ($174-299/month semaglutide, $349 flat tirzepatide). For coaching: Fridays ($150-249/month with 1:1 nutritionist support). For oral tirzepatide: Henry Meds. Patients who specifically value unlimited provider access are the main group for whom Remedy Meds’ premium makes sense.
This page is informational and is not medical advice. This page contains a clearly-marked sponsored placement from SurpassMD, an advertising partner of Peptide Dossier; the editorial assessment of Remedy Meds is independent of that placement. Compounded medications are not FDA-approved. Pricing verified July 2026 and subject to change.